Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Actinium Pharmaceuticals Inc (NY: ATNM )

1.470 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Actinium Pharmaceuticals Inc

< Previous 1 2 3 Next >
Actinium Shares Are Trading Higher After Positive Data From Acute Myeloid Leukemia Trial
Via Benzinga
Actinium (ATNM) Stock Pops on Positive Trial Results
Actinium Pharmaceuticals (ATNM) stock is gaining on Monday after posting positive results from a Phase 3 clinical trial. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back and get ready for another week of trading as we break down the biggest pre-market stock movers for Monday morning! 
Via InvestorPlace
Actinium Pharmaceuticals’ Q4 Phase 3 Trial Updates Could Make Expected Milestones 2023 Catalysts ($ATNM)
Via AB Newswire
Actinium Pharmaceuticals’ Investor Update Puts Clinical Milestones And Potential Catalysts In The Crosshairs ($ATNM)
Via AB Newswire
With Upcoming Pivotal Data, Analyst Sees 145% Upside In Actinium
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2022
  
Via Benzinga
Top Cheap Stocks: Trading Opportunities For Next Week
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some cheap stock opportunities by analyzing... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades 
Via Benzinga
Biotech Stocks News: What’s Going on With LIXT, PTE, QLGN and ATNM Stocks Today?
Biotech stocks are up today amid an influx of positive news. Here's what investors need to know as these small companies skyrocket. 
Via InvestorPlace
Benzinga's Daily Brief On Trending Tickers For April 12, 2022: Veru, Kohl's Corporation, BioCardia, And More
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news... 
Via Benzinga
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Actinium Pharmaceuticals Stock Is Surging
Actinium Pharmaceuticals Inc (AMEX:ATNM) shares are trading higher Tuesday morning after the company announced it entered into a license and supply agreement with Immedica... 
Via Benzinga
Actinium Pharmaceuticals Rally Takes Stock 62% Higher As Its Iomab-B Data Continues To Impress (NYSE AMERICAN: ATNM)
Via AB Newswire
Exposures Product Safety
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Actinium Pharmaceuticals Rally Intact As Its Iomab-B Data Shows 100% Effectiveness In Targeted Patient Population (NYSE AMERICAN: ATNM)
Via AB Newswire
Actinium Pharmaceuticals Stock Jumps 17% Ahead Of SIERRA Trial Update; Iomab-B Shows 100% Effectiveness In Targeted Patient Population (NYSE AMERICAN: ATNM)
Via AB Newswire
48 Biggest Movers From Friday
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by... 
Via Benzinga
Why Actinium Pharmaceuticals' Stock Is Trading Higher Today
Actinium Pharmaceuticals (AMEX:ATNM) shares are trading higher after the company announced it completed enrollment in the pivotal Phase 3 SIERRA trial of iomab-B.... 
Via Benzinga
53 Biggest Movers From Yesterday
Gainers DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO at $17 per share. PROCEPT BioRobotics Corporation... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares jumped 177.2% to $19.60 after the company announced the United States Patent and Trademark Office has issued a notice of... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Mid-Day Market Update: monday.com Jumps Following Strong Q2 Results; Kubient Shares Plunge
Midway through trading Tuesday, the Dow traded down 0.81% to 35,336.88 while the NASDAQ fell 0.89% to 14,661.86. The S&P also fell, dropping 0.65% to 4,450.54. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Actinium's Targeted Radiotherapy Achieves 100% Bone Marrow Transplant Engraftment
Actinium Pharmaceuticals Inc (NYSE: ATNM) highlighted data from its pivotal Phase 3 SIERRA trial evaluating Iomab-B in patients with relapsed or refractory Acute... 
Via Benzinga
Actinium Pharmaceuticals Details SIERRA at Benzinga Global Small Cap Business Conference
Actinium Pharmaceuticals Inc. (NYSE: ATNM), a clinical-stage biopharmaceutical company that develops antibody radiation-conjugates (ARC), took part in the Benzinga Global Small... 
Via Benzinga
Actinium Activates Radiation Inside the Body for Target Conditioning of Cancer Cells
Actinium Pharmaceuticals Inc. (NYSE: ATNM), a clinical-stage biopharmaceutical company, is developing antibody radiation-conjugates (ARCs) to combine the targeting ability of... 
Via Benzinga
Small-Cap Biotech Execs On Latest Advancements, Post-Pandemic Return To Fundamentals
At the Benzinga Global Small Cap Conference Thursday, Jason McCarthy, senior managing director at Maxim Group, hosted a panel discussion on how biotech companies are getting back... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.